bioAffinity Technologies, Inc. Increase (Decrease) in Accounts Payable
bioAffinity Technologies, Inc. (BIAF) reported Increase (Decrease) in Accounts Payable of $207.94 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-07
- bioAffinity Technologies, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $133.63K.
- bioAffinity Technologies, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $74.31K, a 81.15% decline year-over-year.
- bioAffinity Technologies, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$178.86K, a 187.52% decline year-over-year.
- bioAffinity Technologies, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$229.08K.
- bioAffinity Technologies, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$225.41K, a 158.93% decline from fiscal 2024.
- bioAffinity Technologies, Inc. increase (decrease) in accounts payable for fiscal 2024 was $382.52K.
- bioAffinity Technologies, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$14.50K, a 112.65% decline from fiscal 2022.
- bioAffinity Technologies, Inc. increase (decrease) in accounts payable for fiscal 2022 was $114.64K, a 193.79% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $133.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $207.94K 10-Q · filed 2026-08-07 | $29.08K derived: sum of 3 quarters · filed 2026-08-07 | -$199.99K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $74.31K 10-Q · filed 2026-05-11 | -$104.55K derived: sum of 2 quarters · filed 2026-05-11 | -$333.63K derived: sum of 3 quarters · filed 2026-05-11 | -$545.37K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$178.86K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$407.94K derived: sum of 2 quarters · filed 2026-03-16 | -$619.68K derived: sum of 3 quarters · filed 2026-08-07 | -$225.41K 10-K · filed 2026-03-16 |
| 2025-09-30 | -$229.08K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$440.82K derived: sum of 2 quarters · filed 2026-08-07 | -$46.55K 10-Q · filed 2025-11-14 | $157.82K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$211.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $182.53K 10-Q · filed 2026-08-07 | $386.90K derived: sum of 3 quarters · filed 2026-08-07 | $321.73K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $394.27K 10-Q · filed 2026-05-11 | $598.64K derived: sum of 2 quarters · filed 2026-05-11 | $533.48K derived: sum of 3 quarters · filed 2026-05-11 | $997.58K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $204.37K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $139.21K derived: sum of 2 quarters · filed 2026-03-16 | $603.32K derived: sum of 3 quarters · filed 2026-03-16 | $382.52K 10-K · filed 2026-03-16 |
| 2024-09-30 | -$65.17K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $398.94K derived: sum of 2 quarters · filed 2025-11-14 | $178.15K 10-Q · filed 2025-11-14 | -$243.19K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $464.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $243.31K 10-Q · filed 2025-08-14 | -$178.02K derived: sum of 3 quarters · filed 2025-08-14 | $399.45K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$220.80K 10-Q · filed 2025-05-15 | -$642.13K derived: sum of 2 quarters · filed 2025-05-15 | -$64.66K derived: sum of 3 quarters · filed 2025-05-15 | -$36.79K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$421.34K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $156.14K derived: sum of 2 quarters · filed 2025-03-31 | $184.00K derived: sum of 3 quarters · filed 2025-03-31 | -$14.50K 10-K · filed 2025-03-31 |
| 2023-09-30 | $577.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $605.34K derived: sum of 2 quarters · filed 2024-11-14 | $406.84K 10-Q · filed 2024-11-14 | $602.20K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $27.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$170.64K 10-Q · filed 2024-08-14 | $24.72K derived: sum of 3 quarters · filed 2024-08-14 | -$410.56K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$198.50K 10-Q · filed 2024-05-15 | -$3.15K derived: sum of 2 quarters · filed 2024-05-15 | -$438.43K derived: sum of 3 quarters · filed 2024-05-15 | -$101.15K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $195.36K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$239.93K derived: sum of 2 quarters · filed 2024-04-01 | $97.35K derived: sum of 3 quarters · filed 2024-04-01 | $114.64K 10-K · filed 2024-04-01 |
| 2022-09-30 | -$435.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$98.01K derived: sum of 2 quarters · filed 2023-11-14 | -$80.72K 10-Q · filed 2023-11-14 | -$109.81K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $337.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $354.56K 10-Q · filed 2023-08-14 | $325.48K derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | $17.28K 10-Q · filed 2023-05-15 | -$11.80K derived: sum of 2 quarters · filed 2023-05-15 | ||
| 2021-12-31 | -$29.08K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $39.02K 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $68.10K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |